• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Zenas BioPharma Inc.

    3/16/26 8:28:59 AM ET
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ZBIO alert in real time by email
    DEFA14A 1 tm261625d3_defa14a.htm DEFA14A

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     

    SCHEDULE 14A 

    Proxy Statement Pursuant to Section 14(a) of the
    Securities Exchange Act of 1934
    (Amendment No.     )

     

    Filed by the Registrant x 

    Filed by a Party other than the Registrant ¨ 

    Check the appropriate box: 

    ¨ 

    Preliminary Proxy Statement 

    ¨ 

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) 

    ¨ 

    Definitive Proxy Statement  

    x 

    Definitive Additional Materials 

    ¨ 

    Soliciting Material under §240.14a-12

     

    Zenas BioPharma, Inc. 

    (Name of Registrant as Specified In Its Charter) 

    (Name of Person(s) Filing Proxy Statement if other than the Registrant)

     

    Payment of Filing Fee (Check all boxes that apply): 

    x 

    No fee required.  

    ¨ 

    Fee paid previously with preliminary materials.  

    ¨ 

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     

     

     

    GRAPHIC

    Your Vote Counts! *Please check the meeting materials for any special requirements for meeting attendance. Smartphone users Point your camera here and vote without entering a control number For complete information and to vote, visit www.ProxyVote.com Control # V84723-P47266 ZENAS BIOPHARMA, INC. 852 WINTER STREET, SUITE 250 WALTHAM, MA 02451 ZENAS BIOPHARMA, INC. 2026 Annual Meeting Vote by May 10, 2026 11:59 PM ET You invested in ZENAS BIOPHARMA, INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on May 11, 2026. Vote Virtually at the Meeting* May 11, 2026 8:00 am ET Virtually at: www.virtualshareholdermeeting.com/ZBIO2026 Get informed before you vote View the Notice and Proxy Statement and Annual Report online OR you can receive a free paper or email copy of the material(s) by requesting prior to April 27, 2026. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.

    GRAPHIC

    Vote at www.ProxyVote.com Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. Voting Items Board Recommends V84724-P47266 THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. 1. To elect the two Class II director nominees named in the Proxy Statement to serve until the 2029 Annual Meeting of Stockholders and until their successors are duly elected and qualified: Nominees: 1a. James Boylan For 1b. Patrick Enright For 2. To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026. For NOTE: To transact any other matters that may properly come before the Annual Meeting or any adjournments or postponements thereof.

    Get the next $ZBIO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ZBIO

    DatePrice TargetRatingAnalyst
    1/5/2026$19.00Overweight → Equal-Weight
    Morgan Stanley
    3/20/2025$35.00Outperform
    Wedbush
    2/4/2025$19.00Outperform
    Wolfe Research
    12/16/2024$30.00Buy
    H.C. Wainwright
    11/5/2024$34.00Buy
    Rodman & Renshaw
    10/8/2024$45.00Buy
    Guggenheim
    10/8/2024$40.00Overweight
    Morgan Stanley
    10/8/2024$35.00Buy
    Jefferies
    More analyst ratings

    $ZBIO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Zenas BioPharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

    - Obexelimab marketing applications for the treatment of IgG4-RD expected to be submitted to the FDA in Q2 2026 and the EMA in H2 2026 based on the Phase 3 INDIGO trial results - - Topline results of the global Phase 2 SunStone trial of obexelimab in SLE expected in Q4 2026 - - New, half-life extended anti-CD-19 and FcγRIIb mAb (ZB014) progressing toward clinical development - - Global orelabrutinib Phase 3 trial for primary progressive multiple sclerosis (MS) ongoing; global Phase 3 trial for non-active secondary progressive MS expected to be initiated in Q1 2026 - - Oral, IL-17AA/AF inhibitor (ZB021) Phase 1 trial expected to be initiated in 2Q 2026 with initial clinical data b

    3/16/26 7:00:00 AM ET
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    WALTHAM, Mass., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ:ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today announced that on February 17, 2026 (the "Grant Date"), the Compensation Committee of the Company's Board of Directors granted non-qualified stock options to purchase an aggregate of 35,700 shares of the Company's common stock ("Stock Options") and an aggregate of 53,625 restricted stock units of the Company's common stock ("RSUs") to newly hired employees of the Company as an induc

    2/20/26 4:15:00 PM ET
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zenas BioPharma Announces Late-Breaking Platform Presentation of Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis at ACTRIMS Forum 2026

    - Obexelimab met the primary endpoint with a 95% relative reduction in new gadolinium (Gd)-enhancing T1 lesions compared with placebo over weeks 8 and 12 (p=0.0009) - - Separately announced 24-week data support the robust and durable activity of obexelimab and further validate its unique inhibitory mechanism of action - - Obexelimab was well tolerated, and no new safety signals were observed - WALTHAM, Mass., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas," "Zenas BioPharma" or the "Company") (NASDAQ:ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients livin

    2/9/26 7:05:00 AM ET
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZBIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Zenas Biopharma downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded Zenas Biopharma from Overweight to Equal-Weight and set a new price target of $19.00

    1/5/26 3:43:35 PM ET
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wedbush initiated coverage on Zenas Biopharma with a new price target

    Wedbush initiated coverage of Zenas Biopharma with a rating of Outperform and set a new price target of $35.00

    3/20/25 8:00:59 AM ET
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wolfe Research initiated coverage on Zenas Biopharma with a new price target

    Wolfe Research initiated coverage of Zenas Biopharma with a rating of Outperform and set a new price target of $19.00

    2/4/25 7:13:29 AM ET
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZBIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lu Hongbo bought $584,662 worth of shares (25,985 units at $22.50) (SEC Form 4)

    4 - Zenas BioPharma, Inc. (0001953926) (Issuer)

    2/13/26 5:35:50 PM ET
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Allen Patricia L bought $499,746 worth of shares (19,860 units at $25.16) (SEC Form 4)

    4 - Zenas BioPharma, Inc. (0001953926) (Issuer)

    2/13/26 5:06:22 PM ET
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Moulder Leon O Jr bought $1,023,720 worth of shares (57,000 units at $17.96), increasing direct ownership by 16% to 423,155 units (SEC Form 4)

    4 - Zenas BioPharma, Inc. (0001953926) (Issuer)

    2/3/26 4:30:13 PM ET
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZBIO
    SEC Filings

    View All

    $ZBIO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form DEFA14A filed by Zenas BioPharma Inc.

    DEFA14A - Zenas BioPharma, Inc. (0001953926) (Filer)

    3/16/26 8:28:59 AM ET
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Zenas BioPharma Inc.

    DEF 14A - Zenas BioPharma, Inc. (0001953926) (Filer)

    3/16/26 8:25:54 AM ET
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Zenas BioPharma Inc.

    S-8 - Zenas BioPharma, Inc. (0001953926) (Filer)

    3/16/26 7:46:38 AM ET
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Lu Hongbo bought $584,662 worth of shares (25,985 units at $22.50) (SEC Form 4)

    4 - Zenas BioPharma, Inc. (0001953926) (Issuer)

    2/13/26 5:35:50 PM ET
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Allen Patricia L bought $499,746 worth of shares (19,860 units at $25.16) (SEC Form 4)

    4 - Zenas BioPharma, Inc. (0001953926) (Issuer)

    2/13/26 5:06:22 PM ET
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Moulder Leon O Jr bought $1,023,720 worth of shares (57,000 units at $17.96), increasing direct ownership by 16% to 423,155 units (SEC Form 4)

    4 - Zenas BioPharma, Inc. (0001953926) (Issuer)

    2/3/26 4:30:13 PM ET
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZBIO
    Leadership Updates

    Live Leadership Updates

    View All

    Zenas BioPharma Appoints Haley Laken, Ph.D., as Chief Scientific Officer

    WALTHAM, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ:ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced the appointment of Haley Laken, Ph.D., as Chief Scientific Officer (CSO). Dr. Laken brings significant scientific insight and leadership experience in research, development operations, R&D strategy and business development. "Haley is an accomplished R&D leader with expertise in translational research, drug development and operations. She has advanced programs through the clinic leading to regulatory approv

    4/7/25 7:05:00 AM ET
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zenas BioPharma Appoints Lisa von Moltke, M.D., as Head of Research and Development and Chief Medical Officer

    –Dr. von Moltke brings over 30 years of deep drug development experience and a proven track record of clinical and regulatory success at both large and emerging global biopharmaceutical companies– WALTHAM, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ:ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced the appointment of Lisa von Moltke, M.D., as its Head of Research and Development and Chief Medical Officer (CMO). Dr. von Moltke brings over 30 years of U.S. and international drug development experience s

    3/17/25 7:05:00 AM ET
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZBIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Zenas BioPharma Inc.

    SC 13G - Zenas BioPharma, Inc. (0001953926) (Subject)

    11/12/24 10:40:28 AM ET
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Zenas BioPharma Inc.

    SC 13G - Zenas BioPharma, Inc. (0001953926) (Subject)

    10/21/24 4:18:16 PM ET
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Zenas BioPharma Inc.

    SC 13G - Zenas BioPharma, Inc. (0001953926) (Subject)

    9/25/24 6:00:11 PM ET
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZBIO
    Financials

    Live finance-specific insights

    View All

    Zenas BioPharma Announces Positive Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD)

    - Obexelimab met the primary endpoint demonstrating a clinically meaningful and highly statistically significant 56% reduction in risk of IgG4-RD flare - - Obexelimab also met and demonstrated statistically significant activity on all four key secondary efficacy endpoints - - Obexelimab was well tolerated and no new safety signals were observed - - Zenas anticipates submitting a Biologics License Application (BLA) to the FDA in the second quarter of 2026 and a Marketing Authorization Application (MAA) to the EMA in the second half of 2026 - - Zenas to host a conference call today, January 5, 2026, at 8:00 a.m. ET - WALTHAM, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc

    1/5/26 7:05:00 AM ET
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Royalty Pharma and Zenas BioPharma Enter Into Obexelimab Funding Agreement for Up to $300 Million

    Initial $75 million to fund the potential U.S. commercial launch of obexelimab for the treatment of IgG4-Related DiseaseAdditional $150 million associated with the upcoming results of the obexelimab Phase 3 INDIGO trial and FDA approval for the treatment of IgG4-Related Disease NEW YORK and WALTHAM, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) and Zenas BioPharma, Inc. (NASDAQ:ZBIO) today announced that Royalty Pharma will provide up to $300 million in funding in exchange for a royalty on sales of obexelimab. "We are delighted to partner with Zenas as they develop obexelimab in IgG4-RD and other autoimmune diseases," said Pablo Legorreta, founder and CEO

    9/2/25 7:15:00 AM ET
    $RPRX
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million

    - Initial $75 million to fund the potential U.S. commercial launch of obexelimab for the treatment of IgG4-Related Disease - - Additional $150 million associated with the upcoming results of the obexelimab Phase 3 INDIGO trial and FDA approval for the treatment of IgG4-Related Disease - WALTHAM, Mass. and New York, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (NASDAQ:ZBIO), and Royalty Pharma plc (NASDAQ:RPRX) today announced that Royalty Pharma will provide up to $300 million in funding in exchange for a royalty on sales of obexelimab. "We are very pleased to partner with Royalty Pharma as we rapidly advance our broad obexelimab program through late-stage development

    9/2/25 7:05:00 AM ET
    $RPRX
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care